About ADP-ribosylhydrolase ARH1
ADP-ribosylhydrolase ARH1 (ADPRH) is a protein
from Homo sapiens identified by UniProt accession
P54922, 357 residues long.
MolForge cross-references it against 0 known binders and
35 disease associations.
Target properties
| Protein name | ADP-ribosylhydrolase ARH1 |
|---|
| UniProt accession | P54922 |
|---|
| Gene | ADPRH |
|---|
| Organism | Homo sapiens |
|---|
| Length | 357 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (35)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.09
- asthma · score 0.08
- varicella, severe recurrent · score 0.07
- candidiasis, familial, 4 · score 0.07
- Vitiligo · score 0.07
- systemic lupus erythematosus · score 0.06
- immunodeficiency 28 · score 0.06
- immunodeficiency 31B · score 0.05
- immunodeficiency 35 · score 0.05
- immunodeficiency due to ficolin3 deficiency · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P54922-F1 | alphafold | PREDICTED | 98.42 | — |
Amino-acid sequence (357 residues)
MEKYVAAMVL SAAGDALGYY NGKWEFLQDG EKIHRQLAQL GGLDALDVGR WRVSDDTVMH LATAEALVEA GKAPKLTQLY YLLAKHYQDC MEDMDGRAPG GASVHNAMQL KPGKPNGWRI PFNSHEGGCG AAMRAMCIGL RFPHHSQLDT LIQVSIESGR MTHHHPTGYL GALASALFTA YAVNSRPPLQ WGKGLMELLP EAKKYIVQSG YFVEENLQHW SYFQTKWENY LKLRGILDGE SAPTFPESFG VKERDQFYTS LSYSGWGGSS GHDAPMIAYD AVLAAGDSWK ELAHRAFFHG GDSDSTAAIA GCWWGVMYGF KGVSPSNYEK LEYRNRLEET ARALYSLGSK EDTVISL
Explore ADP-ribosylhydrolase ARH1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets